TUSTIN, Calif., Dec. 21, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC.PK - News) (OTCPK:RXPC.PK - News), a developer and marketer of cancer tests, today announces it has expanded its distribution agreement with UniPharma Taiwan headquartered in Taipei, Taiwan.
Previously, Radient's agreement with Uni Pharma provided UniPharma the exclusive right to distribute Radient's flagship product Onko-Sure® cancer test in Taiwan. Radient and UniPharma have now expanded the territory to include Singapore, Hong Kong and Macau. As a full-service distribution partner, UniPharma handles regulatory approvals in assigned territories. Onko-Sure® is a non-invasive in vitro diagnostic blood biomarker test for cancer.
Uni Pharma will be receiving its first shipment of test kits this month, December 2011.
With a combined population of over 35 million people, Taiwan, Singapore, Hong Kong, and Macau is a significant health care market. Cancer remains the leading cause of death in Taiwan, according to the latest statistics released by the Taiwan Department of Health on June 15, 2011 (Taiwan Today, June 16 2011). The most prevalent types of cancer are lung cancer, liver cancer and colorectal cancer, the three of which were responsible for over half of all cancer deaths in Taiwan.
"Onko-Sure® is a cost effective, high value In Vitro Diagnostic cancer test that should be included as a valuable diagnostic tool by doctors, clinicians, and other oncology healthcare professionals," stated Terry Lin, General Manager of UniPharma. "The UniPharma team is excited to distribute Onko-Sure® in our assigned territories of Taiwan and now Singapore, Hong Kong, and Macau. UniPharma ha